All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Abbvie, Roche, Bristol Myers Squibb, Pfizer, GSK, Johnson & Johnson, Legend Biotech and Caribou Biosciences. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View multiple myeloma content recommended for you
How do response rates observed in clinical trials translate into real-world outcomes in MM?
Featured:
Shaji KumarDuring the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Shaji Kumar, Mayo Clinic, Rochester, US. We asked, How do response rates observed in clinical trials translate into real-world outcomes in multiple myeloma?
How do response rates observed in clinical trials translate into real-world outcomes in MM?
Kumar discusses the characteristics of patients in clinical trials versus those treated in the real-world setting, highlighting the stringent inclusion/exclusion criteria and their impact on the generalizability of clinical trial results. He then explores how risk status, drug toxicity, and tolerability impact the real-world effectiveness of treatment. Kumar concludes by highlighting the differences between initial response rates seen in clinical trials and how this translates into longer-term outcomes, such as durability of response and progression-free survival.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content